Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study

Cassia B. Wang(Mayo Clinic in Florida), Pashtoon Murtaza Kasi(Cornell University), Axel Grothey(Campbell Clinic), Dorin Colibaseanu(Mayo Clinic in Florida), Tanios Bekaii‐Saab(WinnMed), Faisal Shahjehan(Mayo Clinic in Florida), Zhuo Li(Mayo Clinic in Florida), Amit Merchea(Jacksonville College)
Frontiers in Oncology
February 18, 2019
10.3389/fonc.2019.00076
Cited by 75

Related Papers

Colorectal cancer
|The Lancet|2019|5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
|New England Journal of Medicine|2018|1.1k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954